BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 11, 2004
View Archived Issues
Characterization of dual TACE/MMP inhibitor for rheumatoid arthritis treatment
Read More
OPi completes restructuring
Read More
BioXell and ProSkelia join efforts in osteoporosis drug discovery
Read More
Pfizer completes tender offer for Esperion Therapeutics' common shares
Read More
GTC restructures
Read More
DOR BioPharma updates status of ricin vaccine development program
Read More
Dynavax licenses immunotherapy programs to UCB
Read More
P&G licenses topical antiinfective technology to GMP Companies
Read More
Senju claims new chymase and/or tryptase inhibitors and their use
Read More
Pharmacia scientists report novel telomerase inhibitors in a recent patent
Read More
Novel androgen receptor agonists under study at Kaken
Read More
Kyowa Hakko presents new antidiabetic agents
Read More
Dual D2/5-HT1A agonists with potential in Parkinson's disease therapy
Read More
New ACAT and LDL oxidation inhibitors reported by Sankyo scientists
Read More
Nippon Kayaku claims a novel antineoplastic antibiotic from Streptomyces sp.
Read More
Takeda researchers prepare and test triazole-based DPP-IV inhibitors
Read More
Genasense NDA accepted for review
Read More
Enrollment completed in confirmatory phase III trial of Prestara
Read More
Replagal receives Canadian approval
Read More
PA-457 IND cleared for initiation of clinical trials
Read More
Antares receives milestone payment from Pfizer licensing agreement
Read More
Keryx completes acquisition of Access Oncology
Read More
Fourth phase II trial for AMD-3100 underway
Read More
Update on single-agent Triapine phase II trials
Read More
Comparable results in phase II head-to-head study of TA-1790 and Viagra
Read More
SPA agreement for PRECISE trial with IL13-PE38QQR, program accepted for FDA CMA Pilot 2 program
Read More
Good safety profile found for CAT-192 in diffuse systemic sclerosis
Read More
Studies demonstrate efficacy of Tri-Luma in melasma patients
Read More
Use of infliximab in the treatment of psoriasis, dermatitis, other conditions reported at AAD
Read More
Clinical, other studies of pimecrolimus presented at dermatology congress
Read More